ArticleACS chemical neuroscience2025
Molecular Simulation-Based Insights into the Pharmacological Role of Silk Fibroin in Peripheral Nerve Repair.
Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Biological Potency of Carotenoids Against Alzheimer's Disease: An Integrated Approach of Molecular Docking and Molecular Dynamics.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral nerve injury (PNI) remains a significant clinical challenge, often leading to impaired nerve regeneration and chronic neuropathic pain. Can Si (Silk Fibroin), a key component of traditional Chinese medicine (TCM), has long been recognized for its regenerative properties, yet its molecular mechanisms in PNI treatment remain unexplored. To elucidate the pharmacological actions of Silk Fibroin, an integrative molecular simulation approach was applied. Network pharmacology was employed to identify the most favorable target receptor for PNI, leading to the selection of the glucocorticoid receptor (GR) due to its critical role in inflammation and nerve repair. Molecular docking simulations evaluated the binding affinities of chemical and protein-based compounds from Silk Fibroin to GR, followed by molecular dynamics (MD) simulations to confirm the stability of these interactions under physiological conditions. Pharmacophore modeling identified key structural features essential for bioactivity, while in silico toxicity assessments evaluated the safety profiles of the compounds. Key bioactive compounds from Silk Fibroin, including Catechin, Hesperetin, and Menaquinone-7, demonstrated strong interactions with GR, with MM/PBSA-based binding free energy values of -35.98 -33.65, and -32.13 kcal/mol, respectively. Protein-based compounds, such as Bombyxin A-5 (-228.06 kcal/mol) and small ribosomal subunit protein uS11 (-204.98 kcal/mol), also displayed promising binding affinities, suggesting potential neuroprotective roles. In silico toxicity assessments revealed favorable safety profiles for most of the compounds. This study highlights Silk Fibroin as a promising source of therapeutic agents for PNI. Future studies should focus on the experimental validation of these computational findings through in vitro and in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.